AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma

Pallavi Madhiraju- August 20, 2024 0

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy ... Read More

Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials

Pallavi Madhiraju- December 11, 2023 0

Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual ... Read More

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Raghuram Kadari- December 28, 2022 0

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio ... Read More

Ipsen to acquire American biopharma company Epizyme for $247m

pallavi123- June 27, 2022 0

French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

pallavi123- August 27, 2021 0

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More

Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma

pharmanewsdaily- April 28, 2020 0

Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

pharmanewsdaily- February 17, 2020 0

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular ... Read More

Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma

pharmanewsdaily- November 4, 2018 0

Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of ... Read More

Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma

pharmanewsdaily- October 28, 2018 0

Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed ... Read More